

# Endometrium

**Protocol applies to all carcinomas  
of the endometrium.**

---

*Protocol revision date: January 2005  
Based on AJCC/UICC TNM, 6<sup>th</sup> edition  
and FIGO 2001 Annual Report*

## **Procedures**

- **Cytology** (No Accompanying Checklist)
- **Biopsy**
- **Curettage**
- **Hysterectomy**

## **Authors**

Philip A. Branton, MD

Department of Pathology, Inova Fairfax Hospital, Falls Church, Virginia

William F. Moore, MD

Department of Pathology, USAF Medical Center, Keesler Air Force Base,  
Mississippi

For the Members of the Cancer Committee, College of American Pathologists

**Previous contributor:** Steven G. Silverberg, MD

## **Summary of Changes to Checklist(s)**

*Protocol revision date: January 2005*

No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

## Surgical Pathology Cancer Case Summary (Checklist)

*Protocol revision date: January 2005  
Applies to invasive carcinomas only  
Based on AJCC/UICC TNM, 6<sup>th</sup> edition  
and FIGO 2001 Annual Report*

### \*ENDOMETRIUM: Biopsy

(Note: Use of checklist for biopsy specimens is optional)

\*Patient name:

\*Surgical pathology number:

<b>Note: Check 1 response unless otherwise indicated.</b>
---

### \*MACROSCOPIC

#### \*Specimen Type

- \*  Biopsy
- \*  Curettage
- \*  Other (specify): \_\_\_\_\_
- \*  Not specified

### \*MICROSCOPIC

#### \*Histologic Type

- \*  Endometrioid adenocarcinoma, not otherwise characterized
- \*  Endometrioid adenocarcinoma, secretory (variant)
- \*  Endometrioid adenocarcinoma, ciliated cell (variant)
- \*  Endometrioid adenocarcinoma, with squamous metaplasia
- \*  Adenosquamous carcinoma
- \*  Serous adenocarcinoma
- \*  Clear cell adenocarcinoma
- \*  Mucinous adenocarcinoma
- \*  Squamous cell carcinoma
- \*  Mixed carcinoma (specify types and percentages): \_\_\_\_\_
- \*  Undifferentiated carcinoma
- \*  Other (specify): \_\_\_\_\_
- \*  Carcinoma, type cannot be determined

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**\*Histologic Grade (if applicable)**

(Grading system below applies primarily to endometrioid carcinoma)

- \*  Not applicable
- \*  GX: Cannot be assessed
- \*  G1: 5% or less nonsquamous solid growth
- \*  G2: 6% to 50% nonsquamous solid growth
- \*  G3: More than 50% nonsquamous solid growth
- \*  Other (specify): \_\_\_\_\_

**\*Additional Pathologic Findings (check all that apply)**

- \*  None identified
- \*  Hyperplasia
  - \*  Simple
  - \*  Complex (adenomatous)
- \*  Atypical hyperplasia
  - \*  Simple
  - \*  Complex (adenomatous)
- \*  Other (specify): \_\_\_\_\_

**\*Comment(s)**

**Surgical Pathology Cancer Case Summary (Checklist)**

*Protocol revision date: January 2005  
 Applies to invasive carcinoma only  
 Based on AJCC/UICC TNM, 6<sup>th</sup> edition  
 and FIGO 2001 Annual Report*

**ENDOMETRIUM: Hysterectomy, With or Without Other  
Organs or Tissues**

Patient name:

Surgical pathology number:

<b>Note: Check 1 response unless otherwise indicated.</b>
---

**MACROSCOPIC****Specimen Type**

- Hysterectomy  
 Radical hysterectomy (includes parametria)  
 Pelvic exenteration  
 Other (specify): \_\_\_\_\_  
 Not specified

**\*Tumor Site**

- \*Specify location(s), if known: \_\_\_\_\_  
 \*  Not specified

**Tumor Size**

- Greatest dimension: \_\_\_\_ cm  
 \*Additional dimensions: \_\_\_\_ x \_\_\_\_ cm  
 Cannot be determined (see Comment)

**Other Organs Present (check all that apply)**

- None  
 Right ovary  
 Left ovary  
 Right fallopian tube  
 Left fallopian tube  
 Urinary bladder  
 Vagina  
 Rectum  
 Other(s) (specify): \_\_\_\_\_

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**MICROSCOPIC****Histologic Type**

- Endometrioid adenocarcinoma, not otherwise characterized
- Endometrioid adenocarcinoma, secretory (variant)
- Endometrioid adenocarcinoma, ciliated cell (variant)
- Endometrioid adenocarcinoma, with squamous metaplasia
- Adenosquamous carcinoma
- Serous adenocarcinoma
- Clear cell adenocarcinoma
- Mucinous adenocarcinoma
- Squamous cell carcinoma
- Mixed carcinoma (specify types and percentages): \_\_\_\_\_
- Undifferentiated carcinoma
- Other (specify): \_\_\_\_\_
- Carcinoma, type cannot be determined

**Histologic Grade (if applicable)**

(Grading system below applies primarily to endometrioid carcinoma)

- Not applicable
- GX: Cannot be assessed
- G1: 5% or less nonsquamous solid growth
- G2: 6% to 50% nonsquamous solid growth
- G3: More than 50% nonsquamous solid growth
- Other (specify): \_\_\_\_\_

**Myometrial Invasion**

- No invasion
- Invasion present
  - Specify depth of invasion: \_\_\_\_ mm
  - Specify myometrial thickness: \_\_\_\_ mm

**Pathologic Staging (pTNM [FIGO])**Primary Tumor (pT)

- \_\_\_ pTX [--]: Primary tumor cannot be assessed
- \_\_\_ pT0 [--]: No evidence of primary tumor
- \_\_\_ pTis [0]: Carcinoma in situ
- pT1 [I]: Tumor confined to corpus uteri
- \_\_\_ pT1a [IA]: Tumor limited to endometrium
- \_\_\_ pT1b [IB]: Tumor invades less than one-half of the myometrium
- \_\_\_ pT1c [IC]: Tumor invades one-half or more of the myometrium
- pT2 [II]: Tumor invades cervix, but does not extend beyond uterus
- \_\_\_ pT2a [IIA]: Tumor limited to the glandular epithelium of the endocervix. There is no evidence of connective tissue stromal invasion.
- \_\_\_ pT2b [IIB]: Invasion of the stromal connective tissue of the cervix
- pT3 [III]: Local and/or regional spread as specified in T3a and T3b, and FIGO IIIA and IIIB
- \_\_\_ pT3a [IIIA]: Tumor involves serosa, parametria, and/or adnexa (direct extension or metastasis)
- \* \_\_\_ pT3a [IIIA]: Tumor involves serosa and/or adnexa (direct extension or metastasis) and/or cancer cells in ascites or peritoneal washings
- \_\_\_ pT3b [IIIB]: Involvement of vagina (direct extension or metastasis), rectal or bladder wall (without mucosal involvement), or pelvic wall(s) (frozen pelvis)
- \_\_\_ pT4 [IVA]: Tumor invades bladder mucosa and/or bowel mucosa

Regional Lymph Nodes (pN)

- \_\_\_ pNX: Cannot be assessed
- \_\_\_ pN0: No regional lymph node metastasis
- \_\_\_ pN1 [IIIC]: Regional lymph node metastasis to the pelvic and/or para-aortic lymph nodes
- Specify: Number examined: \_\_\_  
Number involved: \_\_\_

Distant Metastasis (pM)

- \_\_\_ pMX: Cannot be assessed
- \_\_\_ pM1 [IVB]: Distant metastasis (includes metastasis to abdominal lymph nodes other than para-aortic, and/or inguinal lymph nodes; excludes metastasis to vagina, pelvic serosa, or adnexa)
- \*Specify site(s), if known: \_\_\_\_\_

**Margins**

- \_\_\_ Cannot be assessed
- \_\_\_ Uninvolved by invasive carcinoma
- \*Distance of invasive carcinoma from closest margin: \_\_\_ mm
- \*Specify margin: \_\_\_\_\_
- \_\_\_ Involved by invasive carcinoma
- Specify margin(s): \_\_\_\_\_

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)**

- Absent
- Present
- Indeterminate

**\*Additional Pathologic Findings (check all that apply)**

- \*  None identified
- \*  Hyperplasia
  - \*  Simple
  - \*  Complex (adenomatous)
- \*  Atypical hyperplasia
  - \*  Simple
  - \*  Complex (adenomatous)
- \*  Other (specify): \_\_\_\_\_

**\*Comment(s)**

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.